Evaluation of intra- and extracellular activity of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.
(2014) In Antimicrobial Agents and Chemotherapy 58(12). p.7557-7559- Abstract
- We investigated the activity of trimethoprim-sulfamethoxazole (SXT) against Mycobacterium tuberculosis. The MIC distribution of SXT was 0.125/2.4-2/38 mg/L for the 100 isolates tested, including multi- and extensively drug-resistant isolates (MDR/XDR-TB), whereas the intracellular MIC90 of sulfamethoxazole (SMX) for H37Rv was 76 mg/L. In an exploratory analysis using fAUC0-24h/MIC ≥25 as a potential target, the cumulative fraction response was ≥90% at doses ≥2400 mg of SMX. SXT is a potential treatment option for MDR/XDR-TB.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4691052
- author
- Davies Forsman, L ; Schön, T ; Simonsson, U S H ; Bruchfeld, J ; Larsson, M ; Juréen, P ; Sturegård, Erik LU ; Giske, C G and Angeby, K
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Antimicrobial Agents and Chemotherapy
- volume
- 58
- issue
- 12
- pages
- 7557 - 7559
- publisher
- American Society for Microbiology
- external identifiers
-
- pmid:25246405
- wos:000345221000065
- scopus:84912120697
- pmid:25246405
- ISSN
- 1098-6596
- DOI
- 10.1128/AAC.02995-14
- language
- English
- LU publication?
- yes
- id
- 0517dd7a-b403-4386-b2ec-86c1d1b575cb (old id 4691052)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25246405?dopt=Abstract
- date added to LUP
- 2016-04-01 10:26:14
- date last changed
- 2022-04-27 22:03:00
@article{0517dd7a-b403-4386-b2ec-86c1d1b575cb, abstract = {{We investigated the activity of trimethoprim-sulfamethoxazole (SXT) against Mycobacterium tuberculosis. The MIC distribution of SXT was 0.125/2.4-2/38 mg/L for the 100 isolates tested, including multi- and extensively drug-resistant isolates (MDR/XDR-TB), whereas the intracellular MIC90 of sulfamethoxazole (SMX) for H37Rv was 76 mg/L. In an exploratory analysis using fAUC0-24h/MIC ≥25 as a potential target, the cumulative fraction response was ≥90% at doses ≥2400 mg of SMX. SXT is a potential treatment option for MDR/XDR-TB.}}, author = {{Davies Forsman, L and Schön, T and Simonsson, U S H and Bruchfeld, J and Larsson, M and Juréen, P and Sturegård, Erik and Giske, C G and Angeby, K}}, issn = {{1098-6596}}, language = {{eng}}, number = {{12}}, pages = {{7557--7559}}, publisher = {{American Society for Microbiology}}, series = {{Antimicrobial Agents and Chemotherapy}}, title = {{Evaluation of intra- and extracellular activity of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.}}, url = {{http://dx.doi.org/10.1128/AAC.02995-14}}, doi = {{10.1128/AAC.02995-14}}, volume = {{58}}, year = {{2014}}, }